Daniel X. He, Chenpan Nie, Lei Zheng, Ruilin Sun*, Annie X. An, Jian Fei*, Henry Q.X. Li, Davy X. Ouyang
*Shanghai Model Organisms Center, Inc., 3577 Jinke Rd, Shanghai, 201203 China
Blockade of CD47/SIRPα signaling with anti-CD47 antibodies offers a promising anticancer therapeutic approach, by unleashing the phagocytic activity of macrophages against tumor cells.
Preclinical animal models are needed to assess anti-CD47 antibodies as potential anticancer therapeutics. Models need to be immunocompetent and express humanized CD47/SIRPα, to allow full recapitulation of the mode of action of anti-CD47 agents.
We’ve developed a human CD47/SIRPα double knock-in mouse model in combination with engineered murine syngeneic MC38 cells expressing human CD47. This poster details model characterization, as well as efficacy data for anti-hCD47 antibodies alone and in combination with anti-mPD-1 agents.